Cell Based Assays Market worth $25.77 billion by 2030
The report "Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030", is projected to reach USD 25.77 billion by 2030 from an estimated USD 18.13 billion in 2025, at a CAGR of 7.3% during the forecast period. Factors driving the growth of this global market include the increasing need for drug discovery, growing research & development funding and investments, advancements in cancer research, and a rising focus on personalized medicine. Additionally, the integration of artificial intelligence (AI) with cell-based research activities is expected to further support market growth. However, the high cost of cell-based assay products may hinder this growth. Technical challenges associated with cell-based assays could also pose obstacles to the market's expansion.
Browse 564 market data Tables and 60 Figures spread through 448 Pages and in-depth TOC on "Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cell-based-assays-market-119917269.html
The consumables segment accounted for the largest share of the cell-based assays market, by offering, in 2024.
The cell-based assays market is segmented into four main categories: consumables, instruments, software, and services. The consumables segment is further divided into several subcategories, including reagents, assay kits, microplates, cell lines, probes and labels, and other consumables. In 2024, the consumables segment dominated the market. This segment's large share is mainly due to the increasing demand for high-quality reagents, which are essential for ensuring reliable and reproducible results. Furthermore, the growing focus on developing advanced cellular therapies is likely to drive growth in this segment.
The pharmaceutical & biopharmaceutical companies segment accounted for a major market share of the cell-based assays market, by end user, in 2024.
In 2024, pharmaceutical & biopharmaceutical companies led the cell-based assays market. This growth is primarily driven by the increasing demand for drug discovery and development, particularly due to the rising prevalence of cancer. The growing number of research & development activities aimed at creating new pharmaceutical and biotech drugs and therapies is expected to further propel segmental growth. Additionally, a heightened focus on personalized medicine is anticipated to contribute to the segment's expansion. Moreover, increasing investments and funding for cell-based research are expected to promote further growth in the coming years.
The Asia Pacific region is expected to register the highest CAGR during the forecast period of 2025–2030.
The cell-based assays market is divided into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to experience the fastest growth in this market, driven by a heightened focus on developing cell-based therapies, substantial government investments and funding for research and development, and a rapidly expanding healthcare sector. Additionally, the modernization of healthcare infrastructure and the increasing adoption of advanced technologies for research and clinical applications are anticipated to further support the growth of cell-based assays in the Asia Pacific region.
The key players in the cell-based assays market include BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Revvity (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group Plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US), Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), Altogen Labs (US), and BioAgilytix (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets Sales Intelligence enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cell Based Assays Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
